Firmonertinib
Small molecule targets EGFR via inhibition
Trials 76 · started per year
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05821933 Background | Sep 2023 → Sep 2025 overdue | non-small cell lung carcinoma | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07365410 Comparator | Jan → May 2026 overdue | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06668103 Background | Nov 2024 → Dec 2027 expected | non-small cell lung carcinoma | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06452433 Background | Jun 2024 → Dec 2027 expected | non-small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04401059 Comparator | Nov 2020 → Sep 2025 | adenocarcinoma, non-small cell lung carcinoma | Tian Xie | Unknown | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 84 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | firmonertinib | “furmonertinib (firmonertinib) at 2 dose levels” NCT05607550 ↗11“high-dose firmonertinib (240 mg, daily)” NCT06971406 ↗ |
| Known as | Aifisha | “Furmonertinib (brand name: Aifisha, formerly known as alflutinib/AST2818) is a third-generation EGFR TKI independently developed by Shanghai Allist Pharmaceuticals.” NCT06643000 ↗ |
| Known as | alflutinib | “Furmonertinib (brand name: Aifisha, formerly known as alflutinib/AST2818) is a third-generation EGFR TKI independently developed by Shanghai Allist Pharmaceuticals.” NCT06643000 ↗ |
| Known as | Alflutinib mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297258 ↗ |
| Known as | Alflutinib Mesylate | “Alflutinib Mesylate Tablets (AST2818) in Healthy Male Volunteers” NCT03926182 ↗ |
| Known as | AST-2818 MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297258 ↗ |
| Known as | AST2818 | “Furmonertinib (AST2818) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both sensitising EGFR and EGFR Thr790Met (T790M)...” PMID 33780662 ↗ Mar 20216“Furmonertinib (brand name: Aifisha, formerly known as alflutinib/AST2818) is a third-generation EGFR TKI independently developed by Shanghai Allist Pharmaceuticals.” NCT06643000 ↗ “A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, Study to Assess the Efficacy and Safety of Furmonertinib (AST2818) Versus Placebo” NCT04853342 ↗ “Preclinical animal studies further confirm that both Furmonertinib (AST2818) and its metabolite (AST5902) exhibit excellent intracranial distribution.” NCT06945705 ↗ “Alflutinib Mesylate (AST2818)” NCT03787992 ↗ |
| Known as | Firmonertinib Mesilate | “Firmonertinib Mesilate Tablets” NCT06956001 ↗ |
| Known as | Firmonertinib Mesilate Tablets | “Firmonertinib Mesilate Tablets: Oral administration once daily, 80mg per dose, for 3 years or until disease progression or intolerable toxicity occurs.” NCT07182708 ↗ |
| Known as | firmonertinib mesylate | “receive either firmonertinib mesylate (240mg, orally on an empty stomach daily) or platinum containing dual agent chemotherapy” NCT06956001 ↗ |
| Known as | Furmonertinib | “Furmonertinib (AST2818) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both sensitising EGFR and EGFR Thr790Met (T790M)...” PMID 33780662 ↗ Mar 202161“The efficacy of Furmonertinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was evaluated once a week during the treatment phase.” NCT06315686 ↗ “All patients receive first-line oral therapy with standard-dose third-generation EGFR-TKIs (osimertinib, aumolertinib, or furmonertinib).” NCT07637448 ↗ “Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc.” NCT04401059 ↗ “Furmonertinib is a novel third-generation EGFR-TKI with excellent efficacy and a favorable safety profile.” NCT07548060 ↗ “receive furmonertinib for 9 weeks combined with cisplatin/pemetrexed for 3 cycles” NCT05430802 ↗ “Study Drug: Furmonertinib (Shanghai Allist Pharmaceuticals Co.,Ltd.)” NCT06969781 ↗ “RC108 plus Furmonertinib and/or Toripalimab” NCT05821933 ↗ “Furmonertinib: 80 mg per dose, once daily” NCT07458919 ↗ “furmonertinib 160mg once daily” NCT07398599 ↗ |
| Known as | Furmonertinib Mesilate | “The primary endpoint is ORR; the secondary study endpoints include DCR, DOR, DepOR, PFS, OS, CNS ORR, safety and the PK profile of Furmonertinib Mesilate and its metabolites (AST5902).” NCT04858958 ↗1“Furmonertinib Mesilate Tablets” NCT06970639 ↗ |
| Known as | Furmonertinib Mesylate | “Furmonertinib Mesylate：The dose of Furmonertinib Mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.” NCT04671303 ↗ |
| Known as | Furmonertinib(AST2818) | “Furmonertinib(AST2818)” NCT05987826 ↗ |
| Known as | Ivesa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297258 ↗ |
| Action | Inhibit | “Alflutinib (AST2818) is a newly developed third-generation EGFR tyrosine kinase inhibitor selective for EGFR-sensitizing and T790M-resistant mutations.” PMID 32007598 ↗ Jan 2020 |
| Modality | Small molecule | “irreversible, selective, third-generation EGFR tyrosine-kinase inhibitor” PMID 35662408 ↗ Jun 2022 |
| Route | Oral | “patients received alflutinib orally until disease progression, unacceptable toxicity, or subject withdrawal.” PMID 32007598 ↗ Jan 2020 |
| Target | EGFR | “Alflutinib (AST2818) is a newly developed third-generation EGFR tyrosine kinase inhibitor selective for EGFR-sensitizing and T790M-resistant mutations.” PMID 32007598 ↗ Jan 2020 |